Angiotensin II Receptor Antagonist Induces Regression Methods and Results In the in vivo study, we treated SHRs with the nonpeptide Ang II receptor antagonist (0.1, 1, or 10 mg/kg per day) or hydralazine (10 mg/kg per day). Blood pressure was measured by the tail-cuff method, and wall thickness of left ventricle was serially monitored using M-mode echocardiography. Rats were killed at the age of 13, 17, 21, or 25 weeks, and left ventricular (LV) weight, transverse diameter of cardiomyocytes, relative amount of V3 myosin heavy chain (MHC), and degree of interstitial collagen accumulation were examined. Untreated SHRs progressively developed severe hypertension, but treatment with TCV-116 or hydralazine inhibited the increase in blood pressure. Treat-L r eft ventricular hypertrophy (LVH) is considered to be an adaptive process to increased workload.' Recent studies have demonstrated that angiotensin II (Ang II) acts as a growth factor on cardiac myocytes23 and that angiotensin-converting enzyme (ACE) inhibitor induces regression of LVH both in experimental animal models4-6 and in hypertensive patients.7-9 These results suggest the putative role of the hypertension * pressure overload renin-angiotensin system (RAS) in the formation of LVH. Of course, both mechanical and humoral factors have been implicated in the development of LVH, and the effects of ACE inhibitors in antagonizing the growth-promoting influence of Ang II cannot be dissociated from the concomitant systemic hemodynamic effects of these agents. However, a previous study indicating that even a nonantihypertensive dose of ACE inhibitor reversed LVH in thoracic aorta-constricted rats10 strongly suggests involvement of the RAS in the pathogenesis of LVH. Furthermore, a growing body of evidence supports the existence of tissue RAS in individual organs and suggests the potential relevance of cardiac RAS to cardiovascular homeostasis.11,12 A recent study, which showed that Ang II content in the hypertrophied left ventricle of spontaneously hyperten- Echocardiographic study was performed with a HewlettPackard HP Sonos 100 mechanical sector scanner using a single-element transducer with a frequency of 10 MHz, as previously described.24 Conscious rats were held in the supine position so that the transducer could access the left parasternal echo window. M-mode tracings of the LV wall were obtained using a two-dimensional reference sector and were printed on video imaging papers. Using the leading edge method,25 the thickness of interventricular septum (IVS) and posterior wall (PW) were measured from M-mode tracings.
Microscopic Analysis
At the age of 13, 17, 21, and 25 weeks, the rats were killed and their hearts were excised. Hearts were then dissected into atria and right and left ventricles, and the wet weight of each was measured. Four specimens of left ventricle from each group were fixed and embedded in paraffin, and myocardial tissue was examined microscopically with hematoxylin-eosin or Azan staining. Transverse diameter of cardiomyocytes was measured in the LV free wall according to the method previously described by Takemori et al. 26 In brief, 20 different points were chosen randomly in a cross section of Azan-stained myocardium (diameter of cardiac myocytes was measured in micrometers). To determine the degree of collagen fiber accumulation, we selected eight fields randomly from one cross-sectional cut of left ventricle and calculated the ratio of Azan-stained fibrosis area divided by total myocardium area with NIH IMAGE (NIH, Research Service Branch) image analysis software.
Determination of Myosin Heavy Chain Isoform
For myosin heavy chain (MHC) isoform analyses, each left ventricle was immediately frozen in liquid nitrogen and stored at -70°C until analyzed. The LV myosin isozyme profiles were determined by the migration rate of myosin on polyacrylamide gel electrophoresis as previously described by Hoh et al.27 Briefly, frozen hearts were homogenized in 10% glycerol, 20 mmol/L Na4P204, pH 8.8. After centrifugation, the supernatant was analyzed for V1, V2, and V3 MHC isoforms by nondenaturing pyrophosphate gel electropheresis. The 
LV Wall Thickness on Echocardiography
The two-dimensional long-axis image was clear enough to obtain adequate M-mode tracings; thicknesses of the IVS and PW were measured from M-mode images during five successive beats (Fig 1) . The thicknesses of IVS and PW, which increased progressively along with the elevation of blood pressure in vehicletreated SHRs, were reduced in TCV-116-treated SHRs in a dose-dependent manner. In rats treated with hydralazine, LV wall thickness was also reduced to the same level as that of 0.1 mg/kg per day of TCV-116-treated rats (Fig 2) .
LV Weight
Although systolic blood pressure had been elevated and LV wall thickness had been significantly increased in 13-week-old SHRs compared with age-matched WKY rats, treatment with TCV-116 thereafter reduced the LV weight in a dose-dependent fashion. On the other hand, although hydralazine slightly decreased LV wall thickness according to the echocardiogram (Fig 2) , it did not suppress the increase in LV weight (Fig 3) .
Microscopic Analysis
The transverse diameter of cardiac myocytes progressively increased from the age of 9 weeks to 17 weeks in vehicle-treated SHRs, and treatment with 1 mg/kg per day of TCV-116 inhibited this increase significantly (Fig  4) . creased anatomic LV weight, echocardiographic LV wall thickness, and transverse diameter of myocytes and that hydralazine did not reduce LV weight but slightly decreased LV wall thickness. These results suggest that (1) TCV-116 induces significant regression of LVH, (2) hydralazine also slightly prevents the progression of LVH, and (3) LV wall thickness measured by echocardiography is thought to be a more sensitive parameter of cardiac hypertrophy than LV weight. Echocardiography has been used widely in clinical studies of cardiac hypertrophy, and its usefulness is generally recognized. Our present study revealed that echocardiography is useful in small animals as well as in humans, especially for serial evaluation of the efficacy of drug treatment in experimental animal models of LVH.
Previous studies in animal models demonstrating that ACE inhibitors suppressed hypertrophy-associated ventricular remodeling such as the shift of MHC isoforms from V1 to V3 or the interstitial fibrosis of myocardium39, 40 
